Summarized by Masters of Longevity from Lifespan.io.
Report on a study testing late-life GLP-1 receptor agonist treatment in aged female mice and its effects on lifespan, physiology, and cellular aging markers.
Key Takeaways
- Daily semaglutide started at 20 months increased median female mouse lifespan from 742 to 834 days, a 12.4% gain.
- Treated mice ate ~24% less, lost more fat than muscle, showed better glucose tolerance, activity, and spatial memory.
- Semaglutide reduced inflammatory and senescence-associated markers and increased hippocampal neurogenesis and muscle mitochondrial gene expression.
